Skip to main navigation
logo
SAB Biotherapeutics Logo
  • OVERVIEW
    Corporate Video Executive Management Board of Directors Board Committees Corporate Governance Scientific Advisory Board
  • Platform
    Scientific Platform Publications
  • Pipeline
    Pipeline Overview SAB-195: CDI SAB 176: Influenza
  • PARTNERING
  • Patients
    C. diff Patient Information Influenza
  • Media
    News & Press Releases Events Presentations Publications
  • Shareholder Services
    Overview SEC Filings Stock Quote & Chart Corporate Governance Board Committees Analyst Coverage RSS Feeds Contact Us

Presentations

SAB Corporate Presentation
March 16, 2023
Next Generation Biologics in Immunology: Solution for Complex Diseases
February 3, 2023
Next Generation Biologics in Immunology: Solution for Complex Diseases
January 20, 2023
CRI-ENCI-AACR Immunotherapy Conference Poster Presentation
December 6, 2022
12th International Plasma Product Biotechnology Conference Presentation
November 3, 2022
12th International Plasma Product Biotechnology Conference Presentation
November 3, 2022
ISIRV OPTIONS XI Conference Presentation: SAB-185 Effective Against Multiple COVID-19 Variants, September 27, 2022
October 4, 2022
ISIRV OPTIONS XI Conference Presentation: Validating SAB-176 Influenza Proof of Concept, September 29, 2022
October 4, 2022
Virtual 2022 Annual R&D Portfolio Update
August 17, 2022
Large Animal Genetic Engineering Summit Presentation: Leveraging Genetically Engineered Ungulates to Produce Novel Human Biotherapeutic
June 7, 2022
Pagination
  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »

Shareholder Tools

  • Print Page
  • Email Alerts
  • RSS
  • Investor FAQs
  • © SAB Biotherapeutics 2023

Footer Links

  • Terms & Conditions
  • Privacy Policy